Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway.

@article{Madec2013LosartanAA,
  title={Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway.},
  author={Anne-Marie Madec and Rom{\'e}o Cassel and S{\'e}verine Dubois and Sylvie Ducreux and Guillaume Vial and M. Chauvin and Aur{\'e}lia Mesnier and Karim Chikh and Domenico Bosco and Jennifer Rieusset and Fabien van Coppenolle and Charles Thivolet},
  journal={FASEB journal : official publication of the Federation of American Societies for Experimental Biology},
  year={2013},
  volume={27 12},
  pages={5122-30}
}
As shown in a large clinical prospective trial, inhibition of the renin-angiotensin system (RAS) can delay the onset of type 2 diabetes in high-risk individuals. We evaluated the beneficial effects of RAS inhibition on β-cell function under glucotoxic conditions. Human islets from 13 donors were cultured in 5.5 mM (controls) or 16.7 mM glucose [high glucose (HG)] for 4 d with or without losartan (5 μM), a selective AT1R blocker, and/or U73122 (2 μM), a selective PLC inhibitor, during the last 2… CONTINUE READING
11 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…